Limited joint mobility is frequently observed in elderly people and in patients suffering from diabetes, who represent a growing segment of the population of western countries. Our review wishes to offer the "state of art" about this interesting topic, which may have important clinical implications, leading to impairment of both basic and instrumental activities of daily living. The main causes of a reduced range of motion are degenerative joint diseases and increased stiffness of collagen tissue. The main biochemical abnormality, common to aging and diabetes, is the non-enzymatic glycosilation of collagen, with advanced glycation end product (AGE) formation, which in turn leads to an increase of collagen cross-links. The most extensive accumulation of AGEs occurs in tissues that contain proteins with low turnover, such as the collagen in the extracellular matrix of articular capsule, ligaments and muscle-tendon units. The increase in collagen cross-linking alters the mechanical properties of these tissues with a decrease in elasticity and tensile strength, and an increase in mechanical stiffness. Besides this, AGEs react with specific cell surface receptors (RAGEs). The engagement of the ligand by RAGEs triggers cell-specific signalling, resulting in enhanced generation of reactive oxygen species and sustained up-regulation of pro-inflammatory mediators and adhesion molecules. An appropriate control of the glucose levels and a diet rich in antioxidant agents are recommended in patients with diabetes. Stretching and strengthening programmes are widely used, in order to prevent and to reduce joint stiffness, but the improvements with physiotherapy are little and short-lasting. Several drugs, which can interfere with AGE formation and removal, or with the cellular effects of AGEs, are under study (among them pyridoxamine, an active form of Vitamin B6, AGE-breaker compounds, glucosamine, rutin and derivatives, soluble RAGE isoforms, and statins). In experimental animal models, these drugs are effective in reducing diabetic complications due to AGE formation; however, further study is necessary before their extensive use in the clinical setting.
instrumental actrvities of daily living. Elderly people are an increasing segment of the population in western countries, and type 2 diabetes is a disease mainly age-related, therefore LJM must be regarded as an important problem of public health.
The main pathogenetic mechanism of joint stiffness is the increase of collagen cross-linkings, due to the non-enzymatic glycosylation of collagen with advanced glycation end-product (AGE) formation (I). Recent studies have expanded our knowledge in this field, paving the way to more effective preventive and therapeutic interventions (I). This review is intended to report the literature data on the clinical features of LJM both in advanced age and in diabetes. Thereafter, the histopathology of joints involved will be considered. An in-depth analysis of basic pathogenetic mechanisms will follow and, finally, prevention and therapy will be discussed.
Clinical and epidemiologicalfeatures
It is currently recognized that in aged people joint mobility is reduced. However, our knowledge on this topic is not well-defined because of the different characteristics of subjects enrolled in systematic studies and the methodological discrepancies between authors (2) . Roach and Miles (3) found a small decline (3-5%), in all mean active Range ofMotions (ROIs) of hip and knee, and a more evident decline (about 20%) only for hip extension in selected subjects with normal articular function.
Studying subjects of both sexes from 60 to 84 years old belonging to the general population, Walker et al. (4) observed an evident reduction of shoulder abduction, flexion and extension and also of elbow flexion and of radioulnar supination in the upper limb. To a lesser extent, the ROMs in other joints were reduced. In the lower limb, hip adduction and medial rotation, knee flexion and ankle plantar flexion were significantly impaired.
An important limitation of the published epidemiological studies across age groups is shown by the lack of information on joint structure. Therefore, it is impossible to state whether LJM is due to the simple aging of tissues or to underlying unknown pathological conditions.
On the other hand, many rheumatological manifestations are associated with diabetes mellitus ( Fig. I) (5) . The LJM of the hand, also known as "diabetic cheiroarthropathy", is characterized by stiff hands, with significant impairment of small joints. The prevalence of this condition ranges from 8% to 50%; this large difference may be explained by several factors, such as examination techniques, characteristics of patients (type I and 2 diabetes, young and elderly subjects), duration of the disease and glycaemic control. More definite rheumatological pathologies of the hand, frequent in subjects with diabetes, are Dupuytren's contracture (DC), Trigger finger and Carpal Tunnel syndrome (5) .
DC is characterized by the thickening, shortening, and fibrosis of palmar fascia. This process results in a flexion contracture of the affected fingers, which is usually painless. Trigger finger (also called "flexor tenosynovitis") manifests as a locking phenomenon on finger flexion. It may occur spontaneously or be reproduced on active or passive finger flexion. DC and Trigger finger may be found in 10-15% of subjects with diabetes vs I% in control population.
Carpal tunnel syndrome (CTS) is due to median nerve compression by the transverse carpal ligament. The symptomatology is characterized by pain and/or paresthesia over the thumb, index, middle, and lateral half of the ring fingers.
Nerve conduction study and ultrasound evaluation of the median nerve and wrist are helpful diagnostic tools. The prevalence of CTS in diabetes has been reported in 11-25% and conversely 5-8% of patients with CTS may have diabetes.
Rotator cuff disease is very common after the age of 50. In the population aged 70 years or more, about 20% of people are symptomatic for shoulder problems, and magnetic resonance imaging studies show that, after 60 years, the prevalence of partial or full thickness tears ranges from 30 to 40% (6) .
A consistent association between rotator cuff disease and diabetes has been clearly demonstrated, whereas the association with other vascular risk factors (smoke, hypercholesterolemia) still deserves further research.
Shoulder adhesive capsulitis ("frozen shoulder") is characterized by the limited mobility of the shoulder joint, with pain at the extremes of motion. It may occur in 10-20% of patients with diabetes and is associated with age, duration of the disease both in type I and type 2 diabetes and poor glycaemic control (7) .
Finally, reduced ankle joint range of motion has been documented in patients with diabetes and is more evident in cases complicated by neuropathy (8) . The limited ankle ROM may restrain forward progression of the tibia on the fixed foot during the stance phase of walking. This, in tum, results in prolonged and excessive weight bearing stress under the metatarsal heads during the foot-floor interaction, which is thought to contribute to the development of foot ulcers in individuals with diabetes mellitus (9) .
Hystopathologic and biochemical changes
The hystopathologic and biochemical changes in diabetes are very similar to those age-related and it is current opinion that diabetes "accelerates" the aging process.
The joint capsule, ligaments and tendons lose their normal glistening white appearance. In the portions more affected, these structures become grey and amorphous and show poorly marked areas, where diffuse, fusiform or nodular thickening may be observed and focal loss of the regular arrangements offibers is evident (10) .
Hystopathology shows that the number of fibroblasts and tenocytes per unit of surface area decreases. The number of collagen fibers is slightly reduced and collagen bundles look disintegrated and frayed. The reduction of elastic fibers is consistent. Discontinuity of tendon fibers, focal hypoechoic areas, and localized ligaments and tendon swelling and thickening are the main findings. The increase in collagen cross-linking widely alters the mechanical properties of tissues, with a decrease in modulus of elasticity, and tensile strength, and an increase in mechanical stiffness (10) .
The number of capillaries per unit of surface area, and therefore the arterial blood flow, is reduced both in diabetes and aging (II).
Pathogenesis
It is commonly accepted that pathogenetic factors of LJM are similar in aging and diabetes. The main factor is represented by the increased stiffness of the capsule, ligaments and tendons.
However, it cannot be ruled out that also muscles may playa role since both in old age and diabetes the collagen content of muscles is increased and the number of contractile fibers is reduced. This is due to the combined action of metabolic disorders and disuse (12) . The most important underlying biochemical abnormality, shared by both conditions, is the non-enzymatic glycosylation of collagen with AGEs formation (I).
Fibrillar type 1 collagen is the most abundant constituent of tendon and ligaments. It consists of two non-helical regions called telopeptides, respectively at the amino-terminal (N) and carboxylterminal (C), and a central triple helical region (13) . Collagenous matrix plays an important role in tissue mechanical strength, and this derives from the formation of intermolecular cross-links between the non-helical domains and the helical domain of adjacent collagen molecules.
Collagen cross-links can be divided into two types: a) lysine hydroxylase (LH) and Iysyl oxidasecontrolled (LOX) cross-links (enzymatic crosslinks) and b) glycation or oxidation-induced AGE cross-link (14) .
The most important aspect in the enzymatic crosslink formation is the coupling of e-amino groups of specific Lys and Hyl residues in the molecule aldehyde. The above-mentioned reaction gives origin respectively to allysine and hydroxyallysine. This occurs via the action of LOX following extracellular aggregation of collagen molecules into fibers (15) .
In contrast to the beneficial effects on collagen strength bestowed by enzymatic cross-links, AGEs cross-linking within collagen fibers is generally thought to deteriorate the biological and mechanical function of tendons and ligaments (1).
Pen is well established as a fluorescent intermolecular cross-linking type of AGEs in connective tissues and can be easily and precisely quantified by high performance liquid chromatography (16) . A major type of nonfluorescent AGEs cross-link is glucosepane, which shows structural similarities with Pen, suggesting that they may be formed by parallel pathways (17) .
Once formed, AGEs can be degraded only when the protein they are linked to is itself degraded, therefore, the most extensive accumulation ofAGEs will occur in tissues that contain proteins with low turnover, such as the collagen in the extracellular matrix of connective tissues (cartilage, bone, tendons and skin).
8esides, AGEs react with the cell surface receptor ofAGEs (RAGE), which consists of an extracellular region containing the ligand-binding domain (a single hydrophobic transmembrane a-helix) and a short cytosolic tail, which is essential for RAGE signalling.
Ligand engagement of RAGE triggers cellspecific signalling, resulting in enhanced generation of reactive oxygen species (ROS), and in the activation of the transcription factor NF-Kb. This, in tum, accelerates AGEs cross-link formation in collagen fibers and leads to sustained upregulation of pro-inflammatory mediators, adhesion molecules and to a dysfunctional cell phenotype (18) .
Collagen cross-link formation and the damage induced by AGE-RAGEs interaction affects tensile strength and post-yield properties ofcollagen tissues. Several studies demonstrate that collagen toughness, as well as stiffness, and the elastic modulus are strongly influenced by enzymatic and AGEs crosslink formation (19) .
Prevention and therapy
As first intervention, an appropriate control of hyperglycaemia, as well as a diet rich in anti-oxidant agents, are mandatory, because it has been shown that the articular damage is more frequent and important in patients affected by diabetes who were badly treated (5) .
Secondly, stretching and strengthening programmes, which have been widely used for a long time, are recommended in order to prevent and reduce joint stiffness. These programmes are safe and can improve the LJM in patients suffering from diabetes and elderly subjects. However, the improvements observed are not relevant and not always do they result in a better overall functioning, which allows an independent living. Moreover, such benefits do not last long (20) .
The Knowledgeofbasic pathogenetic mechanisms paves the way to selective therapeutic interventions with drugs which may' counteract the detrimental effects of AGEs, focusing on inhibition of AGE formation and removal, or interfering with the cellular effects ofAGEs (1).
Aminoguanidine, prototype AGE inhibitor, in animal models of diabetes, proved effective in retarding the full range of diabetic complications, such as nephropathy, neuropathy, retinopathy and vasculopathy (21) . However, clinical trials have been disappointing, because the toxicity of the compound, which reacts with pyridoxal phosphate, negatively affects vitamin 86 metabolism and is a strong inhibitor of nitric oxide synthase. According to Nakamura (22) , a therapy with pyridoxamine, an active form of vitamin 86, or pyridoxal 5' -phosphate, could be beneficial. Since considerable amounts of vitamin 86 are consumed when upregulation of gluconeogenesis takes place in both subclinical and clinical diabetic stages, a latent deficiency of vitamin 86 may provoke impaired LOX-controlled enzymatic cross-linking.
Although vitamin 86 is well known to act as an inhibitor of AGEs, future studies are needed to investigate whether supplementation can ameliorate the detrimental formation of enzymatic AGEs crosslinks in the treatment of diabetes.
Other compounds which can inhibit AGEs formation in experimental conditions are glucosamine, which is currently used in osteoarthritis, and rutin, which is largely present in fruits, vegetables, tea and wine. Some AGE-breaker compounds, such . as N-phenacylthiazolium, N-phenacyI4,5dimethylthiazolium and ALT-711, can chemically destroy the crosslink structure of AGEs. Recent studies on animal models and human trials have shown that these compounds can reduce collagen accumulation in heart and kidney (23) .
Further studies highlight the relevance of soluble RAGE (sRAGE) isoforms in several diseases. Endogenous sRAGE isoforms have been found circulating in plasma and in tissues. Their levels are lower in vascular diseases and diabetes, characterized by ligand-RAGE hyperactivity, suggesting a significant inverse correlation with vascular damage (24) . Impressive results, obtained by administrating recombinant soluble RAGE in animal models, suggest that they may neutralize the ligand-mediated damage by acting as a decoy and blocking diabetic complications andjoint inflammation in experimental models (25) . Finally, in vitro studies show that statins may interfere with RAGE signalling. Such an effect is independent from the lipid-lowering property of the molecule. It consists of the inhibition of ROS generation by oxidant enzymes, including NADPHoxidase and myeloperoxidase, as well as in direct antioxidant and anti-inflammatory effects.
It is to be hoped that in a short time new pharmacological compounds, which may counteract the negative effects of AGEs both in diabetes and aging, may enter therapeutic practice and result in better control of AGE-related complications, including limited joint mobility.
CONCLUSIONS
Ageing and diabetes mellitus are conditions frequently associated, both of which can reduce joint mobility, which, in tum, may lead to the impairment of basic and instrumental activities of daily living.
The main pathogenetic mechanism of joint stiffness is the increase of collagen cross-linking, due to advanced glycation end product formation (I). Moreover, AGEs react with specific cell receptors (RAGE). This interaction results in enhanced generation of reactive oxygen species, and in the activation of the transcription factor NF-kB (11). This, in tum, accelerates AGE cross-link formation in collagen fibers (14) and leads to sustained upregulation of pro-inflammatory mediators, adhesion molecules and to a dysfunctional cell phenotype (11) .
Several drugs may act as AGE inhibitors, and may reduce diabetes complications and agingassociated collagen degeneration in experimental models. However, further study is warranted before transferring these promising results in clinical practice.
On the basis of the considerations previously expressed, it appears mandatory to recognize as early as possible the limited range ofmotion ofjoints in elderly people, and especially in elderly patients with diabetes. Preventive interventions, such as stretching and strengthening programmes, a diet rich in anti-oxidant agents, and an optimal metabolic control may slow the progression towards disability.
